Suspension of marketing authorisations of 17-Hydroxyprogesterone caproate (17- OHPC) due to its ineffectiveness in authorised uses Abdul Qadir Safety Alerts July 9, 2025July 18, 2025SafetyAlert 58-Suspension-of-marketing-authorisations-of-17-OHPC-due-to-its-un-effectivenessDownload Share this:TwitterFacebook
